Milestone Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Its Initial Public Offering
May 14, 2019Milestone Pharmaceuticals Inc., today announced that the underwriters for its initial public offering of common shares have fully exercised their option to purchase an additional 825,000 common shares at the public offering price of $15.00 per share.
More »
Milestone Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
May 8, 2019Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company, today announced the pricing of its upsized initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share.
More »
Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors
May 6, 2019Adynxx, Inc. (Nasdaq: ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology, today announced the completion of its merger with Alliqua BioMedical, Inc.
More »